Acute Myeloid Leukemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, hormonal therapy, and other chemotherapies), By Region, and Competition, 2020-2030F

Market Overview

The Global Acute Myeloid Leukemia Market, valued at USD 1.56 Billion in 2024, is projected to experience a CAGR of 8.90% to reach USD 2.63 Billion by 2030. Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow, characterized by the uncontrolled proliferation of abnormal myeloid blast cells. The market for AML therapies is primarily driven by the increasing global incidence of this disease, coupled with an expanding geriatric population which faces a higher risk of diagnosis. Further market expansion is supported by advancements in diagnostic technologies enabling earlier detection and a growing awareness of the disease among healthcare professionals and the public. According to the American Cancer Society, for 2025, approximately 22,010 people in the United States are estimated to be diagnosed with Acute Myeloid Leukemia.

Government funding for cancer research and supportive policy initiatives also contribute to market growth. However, one significant challenge impeding market expansion is the substantial cost associated with advanced therapeutic regimens, including novel targeted therapies and allogeneic stem cell transplantation, which can limit patient access and strain healthcare systems globally.

Key Market Drivers

The global Acute Myeloid Leukemia market is significantly propelled by continuous advancements in AML research and therapeutic technologies. These innovations expand treatment options and improve patient outcomes through novel drug classes and therapeutic strategies. For instance, according to The Leukemia & Lymphoma Society, in December 2024, the U. S. Food and Drug Administration approved revumenib, the first-in-class menin inhibitor for adults and children with advanced acute myeloid leukemia presenting KMT2A gene translocations. This marks a substantial step in precision oncology for AML. Concurrently, increased government funding and supportive regulatory policies play a pivotal role in accelerating research and development. Such governmental backing fosters scientific exploration and expedites new treatments. According to the National Cancer Institute’s 2024 Budget Fact Book, in fiscal year 2024, the U. S. Congress allocated $7.224 billion to the National Cancer Institute, demonstrating a considerable commitment to cancer research initiatives.

These combined drivers foster a dynamic market, characterized by ongoing innovation and broader accessibility to advanced therapies. Targeted agents and development funding directly address AML's complex genetic heterogeneity, leading to more effective and personalized treatments. This progress is essential given the disease burden; according to a Leukemia & Lymphoma Society news release, in July 2023, approximately 20,000 new patients were diagnosed with acute myeloid leukemia in the United States each year, highlighting the persistent need for improved therapeutic solutions. The interplay of scientific breakthroughs and strategic public investment is critical for future market expansion and enhanced patient quality of life.

Download Free Sample Report

Key Market Challenges

The substantial cost associated with advanced therapeutic regimens presents a significant impediment to the growth of the Global Acute Myeloid Leukemia Market. These high expenses directly affect patient access to potentially life-saving treatments, thereby limiting the overall uptake and revenue potential of innovative therapies. Advanced options, such as novel targeted agents and allogeneic stem cell transplantation, carry considerable price tags that can strain healthcare systems and individual patient finances globally.

Patient access is severely curtailed when therapeutic costs are prohibitive, particularly for long-term management required in AML. For instance, according to the American Society of Hematology, in 2024, the estimated annual cost of certain novel agents like venetoclax can exceed $100,000, contributing to financial toxicity for patients and their families. This financial burden can lead to treatment delays, non-adherence, or a complete inability to commence optimal regimens, directly suppressing the volume of patients receiving these advanced therapies. Consequently, while new treatments may offer improved clinical outcomes, their high cost impedes their widespread adoption and market penetration, ultimately hampering overall market expansion.

Key Market Trends

The increasing utilization of oral and outpatient treatment regimens is significantly reshaping the global Acute Myeloid Leukemia market by enhancing patient convenience and reducing the burden on hospital infrastructure. These innovative approaches enable treatment administration in less restrictive settings, improving the quality of life for patients, particularly the elderly or those with comorbidities. The European Hematology Association (EHA) Congress in June 2025 highlighted advancements in tablet-only treatment combinations, such as decitabine-cedazuridine with venetoclax, designed to offer effective therapy at home, thereby minimizing the necessity for frequent clinic visits. In a relevant development, a phase 2 study for the oral menin inhibitor ziftomenib, for relapsed/refractory NPM1-mutated AML, demonstrated that by late 2024, 23% (21 of 92 patients) achieved complete response or complete response with partial hematological recovery in trials conducted by Roswell Park Comprehensive Cancer Center and collaborators, as reported in May 2025.

The expanding market presence and investment in the Asia-Pacific region represents another pivotal trend, driven by the substantial patient population and growing healthcare expenditures. This region presents significant opportunities for pharmaceutical companies to introduce novel therapies and diagnostics. According to the Global Burden of Disease data, as published in January 2025, East Asia reported a leukemia prevalence rate of 20.57 per 100,000 individuals, indicating a large potential patient base across the broader Asia-Pacific area. This demographic landscape encourages strategic partnerships and investments. For instance, in November 2024, Kyowa Kirin Co. , Ltd. and Kura Oncology, Inc. announced a global strategic partnership to develop and market ziftomenib, a selective oral menin inhibitor, for hematologic malignancies including acute myeloid leukemia. This exemplifies the rising corporate focus on developing and commercializing advanced AML treatments within the region.

Regional Insights

North America consistently leads the Global Acute Myeloid Leukemia Market due to its robust healthcare infrastructure, substantial investments in research and development, and the significant presence of major pharmaceutical companies. The region benefits from strong regulatory support, with the U. S. Food and Drug Administration (FDA) facilitating expedited pathways for novel AML therapies. Furthermore, high healthcare expenditure and favorable reimbursement policies enhance patient access to advanced treatments, including targeted therapies and immunotherapies. This combination of an innovative ecosystem, regulatory efficiency, and accessible specialized care drives North America's market dominance.

Recent Developments

• In August 2025, Pfizer received approval from the U.S. Food and Drug Administration for its product, PF-07220060. This newly approved targeted therapy represents a first-in-class treatment specifically for patients with relapsed/refractory acute myeloid leukemia (AML) who present with FLT3 mutations. The regulatory clearance offers an important additional therapeutic avenue for individuals within high-risk AML patient populations, addressing a recognized area of significant medical need. This development underscores an advancement in personalized medicine strategies for genetically defined subtypes of AML.

• In July 2025, Servier announced the publication of long-term follow-up data from its Phase 3 AGILE trial regarding TIBSOVO® (ivosidenib) in IDH1-mutated acute myeloid leukemia (AML). The comprehensive results, featured in Blood Advances, continued to demonstrate a sustained survival benefit for patients who received TIBSOVO in combination with azacitidine when compared to those on placebo-azacitidine. The analysis revealed a significantly extended median overall survival within the TIBSOVO combination arm. These findings further establish TIBSOVO as a standard of care for newly diagnosed IDH1-mutated AML patients ineligible for intensive chemotherapy.

• In December 2024, the U.S. Food and Drug Administration granted approval for revumenib (Revuforj®), introducing a new treatment option for specific forms of acute myeloid leukemia (AML). This first-in-class menin inhibitor received approval for use in adults and children aged one year and older who have advanced AML characterized by a KMT2A gene translocation. Clinical trials demonstrated that a notable percentage of patients achieved complete remission, with many subsequently proceeding to potentially curative stem-cell transplants. This regulatory milestone addresses a high unmet medical need within a challenging type of leukemia.

• In February 2024, Gilead Sciences announced the discontinuation of its Phase 3 ENHANCE-3 study, which was evaluating the investigational drug magrolimab in combination therapies for acute myeloid leukemia (AML). This decision followed an independent Data Monitoring Committee’s interim analysis, which indicated both futility and an increased risk of death, primarily attributed to infections and respiratory failure, within the magrolimab treatment arm. Consequently, the U.S. Food and Drug Administration placed all ongoing magrolimab studies in myelodysplastic syndromes and AML on a full clinical hold. Gilead confirmed it would not pursue further development of magrolimab for hematologic cancers.

Key Market Players

• Bristol-Myers Squibb Company (Celgene Corporation)
• Novartis AG
• Genmab AS
• Otsuka Holdings Co. Ltd
• Sanofi-Aventis (Genzyme Corporation)
• Teva Pharmaceutical (Cephalon Inc.)
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Sunesis Pharmaceuticals Inc.
• Astellas Pharma
• Oncolyze Inc.

Report Scope:

In this report, the Global Acute Myeloid Leukemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Acute Myeloid Leukemia Market, By Chemotherapy:

o   Cytarabine

o   Anthracycline Drugs

o   Alkylating Agents

o   Anti-metabolites

o   Tyrosine Kinase Inhibitors

o   Hormonal therapy

o   Other chemotherapies

• Acute Myeloid Leukemia Market, By Region:

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

o   South America

§  Brazil

§  Argentina

§  Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Acute Myeloid Leukemia Market.

Available Customizations:

Global Acute Myeloid Leukemia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Acute Myeloid Leukemia Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]